Posted by Michael Wonder on 02 Oct 2021
Formycon and Bioeq announce file acceptance for FYB201, a biosimilar candidate to Lucentis (ranibizumab) by the U.S. FDA
1 October 2021 - Formycon and its license partner Bioeq announce that the U.S. FDA accepted the biologics license application for FYB201, a biosimilar candidate to Lucentis, for review and assigned a target action date for the application for August 2022.
Bioeq submitted the biologics license application to the FDA in August 2021.
